Here's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today

MarketsMotley Fool

What happened

La Jolla Pharmaceutical (NASDAQ: LJPC) shares surged by 12.5% as of 12 p.m. EST Friday after the FDA approved the company's first commercial drug.

Continue Reading Below

So what

Earlier this year, La Jolla Pharmaceutical reported positive phase 3 results data for Giapreza (formerly LJPC-501), a medicine that can help patients suffering from a life-threatening drop in blood pressure. Management filed for FDA approval shortly thereafter, but a decision from the regulator wasn't expected until Feb. 28, 2018.

Instead, the FDA gave La Jolla Pharmaceutical and its investors a Christmas present, approving Giapreza about two months ahead of schedule.

In trials, Giapreza successfully increased the proportion of patients achieving a mean arterial pressure of at least 75 mmHg, or a 10 mmHg increase from baseline, three hours following the initiation of treatment, without increasing the need for standard-of-care vasopressors.

Now what

The company is targeting a March 2018 launch for Giapreza, so we won't get any insight into how rapidly doctors and hospitals will add it to their treatment arsenals until the second quarter.

That said, there is an opportunity for this drug to become a meaningful source of sales for La Jolla Pharmaceutical. There's a relatively high mortality rate associated with shock patients who don't respond to existing treatment options, and the addressable market of Giapreza is on the scale of hundreds of thousands of patients per year in the U.S. alone.

10 stocks we like better than La Jolla PharmaceuticalWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and La Jolla Pharmaceutical wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of December 4, 2017

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.